The Singapore Health Sciences Authority (HSA) has accepted Everest Medicines’ new drug application (NDA) for Nefecon to treat adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.

Singapore has therefore become the second country to accept the NDA, following mainland China in November 2022.

Nefecon expects to secure NDA approval in Singapore this year.

Everest Medicines CEO Rogers Yongqing Luo said: “This milestone is a testament to Everest’s ability to successfully advance much-needed, first-in-disease drug candidates through regulatory pathways across multiple regions in Asia, as we work to bring critical treatment options to patients as quickly as possible.

“We also plan to submit NDAs for Nefecon in South Korea, Hong Kong and Taiwan this year.

“Renal disease is a key focus area for Everest, and disease prevalence in Asia is much higher than in other areas of the world. Leading with Nefecon as our anchor product, we are building a pipeline of promising renal drug candidates to address huge unmet medical needs.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Everest’s NDA for Nefecon in mainland China is currently under priority review and is expected to receive clearance by the second half of 2023.

Nefecon represents the first non-oncology medicine to gain breakthrough therapy designation in China.

Everest stated that it has the potential to become a first-in-disease therapeutic option for around five million IgAN patients in the country.

In February 2023, Nefecon received a global innovative product on fast track (GIFT) designation from South Korea’s Ministry of Food and Drug Safety (MFDS).

The designation made Nefecon the first non-oncology product in the programme.

In November 2022, the Taiwan Food and Drug Administration granted accelerated approval designation (AAD) to Nefecon.